



It Is Time

**Kiran K. Turaga, MD, MPH¹, T. Clark Gamblin, MD, MS, MBA², Robert Edwards, MD, PhD³,
H. Richard Alexander, MD, PhD⁴, and David Bartlett, MD⁵**

¹Department of Surgery, University of Chicago, Chicago, IL; ²Department of Surgery, Medical College of Wisconsin, Milwaukee, WI; ³Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA; ⁴Department of Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; ⁵Department of Surgery, University of Pittsburgh, Pittsburgh, PA

In this series, we present selected articles presented at the SSO International Symposium of Regional Therapies at Jacksonville in 2018. The symposium, which was supported by the Society of Surgical Oncology, resulted in a record turnout and a great scientific discussion. In addition to laying grounds for scientific advances and collaboration, the meeting provided a family-friendly venue for networking, mentoring, and new ideas.

Management of regional metastases with locoregional therapies has long been studied, and the year 2018 saw some remarkable advances. Evidence regarding the role of locoregional (HIPEC) therapy for peritoneal metastases of colorectal and ovarian origin was presented, which confirmed the efficacy of intraperitoneal therapy in ovarian tumors and in a select group of patients with peritoneal metastases from colorectal malignancies. The science behind melanoma immunotherapy has been supercharged, and the results of new trials of checkpoint inhibitors, elucidation of mechanisms of “cold” immune environments, IDO inhibitors, and inhibition of the MAP-Kinase pathway and the role of such therapies in adjuvant settings became

mainstream. The field of liver metastases has matured in its understanding of catheter-based, regional therapies, and the evolution of modern therapies, such as ALPPS, two-stage liver resections, and liver transplants. Regional perfusion clinical trials remain active, and results are awaited.

The articles presented in this series focus on three themes: (1) the novel application of regional therapies to benign and malignant disease; (2) the role of perioperative outcomes and toxicity on oncological outcomes; and (3) patient-centered (and specific) optimization of therapies. A visual abstract summary of the articles is depicted in Fig. 1a–l.

With the rapid advancements in the field, it is time that regional therapies for locally advanced disease continue to advance and augment evolving therapies. Momentum in collaboration through the development of cooperative working groups, consensus conferences, and novel societies are reflective of the heightened interest in this field. Simultaneous with advances in the management of these diseases, advances in imaging, pathology, and translational research need to occur. Come join us in Phoenix this year to contribute to this evolving field!











FIG. 1 a–m Visual abstracts of cancer regional therapies series








FIG. 1 continued

REFERENCES

- Perez MC, Miura JT, Naqvi SMH, et al. Talimogene Laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. *Ann Surg Oncol.* 2018;25:3960. <https://doi.org/10.1245/s10434-018-6803-0>.
- Silva JP, Klooster B, Tsai S, et al. Elective regional therapy treatment for hepatic adenoma. *Ann Surg Oncol.* 2018. <https://doi.org/10.1245/s10434-018-6802-1>.
- Roxburgh CS, Fenig YM, Cercek A, et al. Outcomes of low-grade appendiceal mucinous neoplasms with remote acellular mucinous peritoneal deposits. *Ann Surg Oncol.* 2018. <https://doi.org/10.1245/s10434-018-7003-7>.
- Munoz-Zuluaga C, Sardi A, King MC, et al. Outcomes in peritoneal dissemination from signet ring cell carcinoma of the

- appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol.* 2018. <https://doi.org/10.1245/s10434-018-7007-3>.
- Katsarelis D, Rådbo E, Ben-Shabat I, et al. The effect of temperature and perfusion time on response, toxicity, and survival in patients with in-transit melanoma metastases treated with isolated limb perfusion. *Ann Surg Oncol.* 2018;25:1836. <https://doi.org/10.1245/s10434-018-6459-9>.
- Belgrano V, Pettersson J, Nilsson JA, et al. Response and toxicity of repeated isolated limb perfusion (re-ILP) for patients with in-transit metastases of malignant melanoma. *Ann Surg Oncol.* 2019. <https://doi.org/10.1245/s10434-018-07143-4>.
- Hendrix RJ, Damle A, Williams C, et al. Restrictive intraoperative fluid therapy is associated with decreased morbidity and length of stay following hyperthermic intraperitoneal

- chemoperfusion. *Ann Surg Oncol*. 2018. <https://doi.org/10.1245/s10434-018-07092-y>.
8. Anghelescu DL, Brown CL, Murphy AJ, et al. Anesthesia and pain management for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for desmoplastic small round cell tumors in children, adolescents, and young adults. *Ann Surg Oncol*. 2018. <https://doi.org/10.1245/s10434-018-6808-8>.
 9. Choudry MHA, Shuai Y, Jones HL, et al. Postoperative complications independently predict cancer-related survival in peritoneal malignancies. *Ann Surg Oncol*. 2018;25:3950. <https://doi.org/10.1245/s10434-018-6823-9>.
 10. Beane JD, Wilson GC, Sutton JM, et al. Pleuropulmonary recurrence following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for appendiceal *Pseudomyxoma peritonei*. *Ann Surg Oncol*. 2019. <https://doi.org/10.1245/s10434-018-07091-z>.
 11. Feferman Y, Solomon D, Bhagwandin S, et al. Sites of recurrence after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis from colorectal and appendiceal adenocarcinoma: a tertiary center experience. *Ann Surg Oncol*. 2018. <https://doi.org/10.1245/s10434-018-6860-4>.
 12. Francescutti VA, Maciver AH, Stewart E, et al. Characterizing the patient experience of CS/HIPEC through in-depth interviews with patients: identification of key concepts in the development of a patient-centered program. *Ann Surg Oncol*. 2019. <https://doi.org/10.1245/s10434-018-07120-x>.
 13. Votanopoulos KI, Mazzocchi A, Sivakumar H, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. *Ann Surg Oncol*. 2018. <https://doi.org/10.1245/s10434-018-7008-2>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.